Currently (2018) Michael Gilman is the CEO of two biotech startups – Arrakis Therapeutics, a company attempting to make small molecule drugs against RNA targets;…
Jérémie Meyer30.05.2018
Basel-based pharmaceutical company Novartis has received approval in the USA for its Aimovig migraine medication, developed with its partner, Amgen. It is a new therapeutic…
Jérémie Meyer22.05.2018
Basel is among the European biotech hubs with the most exciting companies as named by labiotech.eu. The industry platform highlighted businesses including Actelion, CRISPR Therapeutics…
Jérémie Meyer18.05.2018
The Swiss biotech industry continued to grow in 2017. Reaching record figures in sales and capital investments in companies, according to a new report. New…
Jérémie Meyer14.05.2018
Targeted protein degradation is really taking off. Besides Arvinas, C4 Therapeutics, and Kymera, Cedilla Therapeutics, founded by Thirdrock Ventures, has emerged with a $56 million…
Jérémie Meyer26.04.2018
The patent law and attorney-at-law firm Vossius & Partner has been an important partner for BaseLaunch since the inception of the healthcare accelerator in 2016.…
Jérémie Meyer24.04.2018
This blog was written by Tariq Kassum, COO and Head of Corporate Development at Obsidian Therapeutics, as part of the From The Trenches feature of…
Jérémie Meyer17.04.2018